leisure time -WSS

leisure time

author：fashion 2025-08-23 05:00:32 - browse：1

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： The future of health care in the House

entertainment

hotspot

WSS

Why age limits for politicians are a terrible idea

Stroke deaths set to near 10 million globally by 2050

Indictment alleges Trump's ex

Bird flu researchers hone in on Finland’s mink farms

Dozens dead from Maui wildfires: What we know about the victims

Be careful with at

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

Be careful with at

After affirmative action ruling, medical educators look to 'holistic review'

Idaho college killings prosecutors challenge defense's grand jury claims

United colonoscopy coverage change 'may cost lives,' doctors say

Treatments for cramps don't cut it. Why aren't there better options?

Affirmative action in medical school literally saved lives

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Indictment alleges Trump's ex

explore

Chan Zuckerberg Biohub Chicago to focus on inflammation

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Histogen: Failed biotech offers rare public look inside

Biden administration begins canceling student loan debt for 804,000 borrowers

Liquid biopsy for lung cancer is launched by Delfi

Phenylephrine and the overlooked value of the placebo effect

entertainment

entertainment

hotspot

leisure time